Ascendia

  MARKET NEWS

European Patent Office to Grant ZyVersa Therapeutics’ Patent Application for Cholesterol Transport Mediator for Use in Patients With Diabetic Nephropathy/Diabetic Kidney Disease
Anavex Life Sciences Announces Completion of Phase 2/3 Rett Syndrome Clinical Trial
Catalent Expands OneBio® Suite for Integrated Development, Manufacturing & Supply Across Biologic Modalities
Enterin Announces the Start of a First-in-Human Study of ENT-03 in Obesity & Type 2 Diabetes
Synlogic Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of Phenylketonuria
Portage Biotech Reports Updated Interim Data for Lead iNKT Engager in Phase 1/2 Trial for the Treatment of Advanced Melanoma & Metastatic Non-Small Cell Lung Cancer

  FEATURED EDITORIAL

 

  COMPANY PROFILE

Lifecore Biomedical is a fully integrated Contract Development and Manufacturing Organization (CDMO) with expertise in specialty formulation, aseptic filling, and final packaging of complex medical devices and injectable pharmaceuticals. Lifecore has also been a leading producer of pharmaceutical-grade, non-animal-sourced sodium hyaluronate since 1981 when we developed our fermentation-based process. Since then, we have become the preferred viscoelastic supplier to ophthalmic market leaders and our products have been used in the treatment of more than 150 million patients worldwide. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Needle-Free Vaccine Delivery Platform Aims to End Frozen Storage Needs & Improve Access

Needle-Free Vaccine Delivery Platform Aims to End Frozen Storage Needs & Improve Access

aVaxziPen’s innovative vaccine delivery platform aims to improve access to vaccines by removing the need for frozen storage and enabling easier distribution and deployment….

Ajinomoto Integrates R&D Sites in Japan & Korea With Genedata Bioprocess

Ajinomoto Integrates R&D Sites in Japan & Korea With Genedata Bioprocess

Genedata and Ajinomoto recently announced Ajinomoto has successfully rolled out Genedata Bioprocess® to its Korean sites, Ajinomoto Genexine, in line with….

Imbria Pharmaceuticals Completes Enrollment in Phase 2 IMPROVE-HCM Trial of Ninerafaxstat in Patients With Non-Obstructive Hypertrophic Cardiomyopathy

Imbria Pharmaceuticals Completes Enrollment in Phase 2 IMPROVE-HCM Trial of Ninerafaxstat in Patients With Non-Obstructive Hypertrophic Cardiomyopathy

Imbria Pharmaceuticals, Inc. recently announced it has completed enrollment in the IMPROVE-HCM Phase 2 placebo controlled clinical trial of ninerafaxstat with 67….

NovelMed Phase 1 Clinical Trial Shows Inhibition of the Alternative Pathway & Preservation of the Classical Pathway – A Long-Acting Anti-Properdin Monoclonal Antibody for PNH Patients

NovelMed Phase 1 Clinical Trial Shows Inhibition of the Alternative Pathway & Preservation of the Classical Pathway – A Long-Acting Anti-Properdin Monoclonal Antibody for PNH Patients

NovelMed Therapeutics, Inc. recently announced topline results from First-in-Human Phase 1 clinical trial of its complement blocker monoclonal anti-Properdin antibody, known as NM3086…..

  WHITEPAPERS & WEBINARS

ON-DEMAND WEBINAR – Solve Common Design Challenges in Inhalation Devices With Porous Polymers

ON-DEMAND WEBINAR – Solve Common Design Challenges in Inhalation Devices With Porous Polymers

The effectiveness of inhalation devices relies on their ability to deliver the pharmaceutical directly to the targeted part of the body with precision and calculated dosing.  Since these devices….

ON-DEMAND WEBINAR - CMC Strategy to Take Bispecifics From DNA to IND in 13 Months* by Lonza

ON-DEMAND WEBINAR - CMC Strategy to Take Bispecifics From DNA to IND in 13 Months* by Lonza

Lonza has applied it’s 35 years of CMC experience in Biologics to develop an end-to-end comprehensive DS/DP DNA to IND strategy in 13 months. This presentation….

ON-DEMAND WEBINAR - Exploring Pectin & the Advancement of Delayed Release Technology

ON-DEMAND WEBINAR - Exploring Pectin & the Advancement of Delayed Release Technology

In this webinar, experts will provide an overview of why the properties and structure of pectin are well suited for site-specific delivery to the colon. In addition, experts will also provide insights into how softgel capsules, formed by the combination of both pectin and gelatin, are used in OptiGel® DR, a new delayed release delivery technology for pharmaceutical applications.

  WHITEPAPERS & WEBINARS

APPLICATION NOTE: Process Optimization & Preclinical Production Using the ANP System

APPLICATION NOTE: Process Optimization & Preclinical Production Using the ANP System

Particle Works is thrilled to announce the launch of a new Application Note that delves into the advancement of nanoparticles as carriers for targeted drug delivery. Developing nanoparticles for this purpose can be intricate and demanding, necessitating consistent, cost-effective, and …

TECH BRIEF – Expedite FDA Approvals With Certified Pure Materials

TECH BRIEF – Expedite FDA Approvals With Certified Pure Materials

A key focus of the U.S. Food and Drug Administration’s evaluation of a medical device’s safety and effectiveness is reviewing its material makeup. If improperly tested – and impure materials are used – there is an elevated risk of contamination …

WHITEPAPER - How to Mitigate Risk for Biologics During Fill/Finish Manufacturing

WHITEPAPER - How to Mitigate Risk for Biologics During Fill/Finish Manufacturing

Aseptic processing with the highest degree of sterility assurance, filling accuracy, and quality is critical for high-value, small-batch therapies. This white paper explores the specialized equipment, expertise, and services needed for efficient biologics fill/finish manufacturing.

CLICK HERE TO DOWNLOAD/VIEW THE …

WHITEPAPER - Extrusion-Spheronization, Engineered for Today’s Controlled Release Forms

WHITEPAPER - Extrusion-Spheronization, Engineered for Today’s Controlled Release Forms

 

Synchronizing and controlling API delivery, Extrusion-Spheronization (E-S) offers pharmaceutical drug developers a robust technique to develop and manufacture today’s most complex oral sold dose therapeutics.

Manufacturing oral solid dose API’s into spheres via Extrusion-Spheronization is not new. What is …

WHITEPAPER - Unique Manufacturing Challenges Associated With Sterile Eye Ointments

WHITEPAPER - Unique Manufacturing Challenges Associated With Sterile Eye Ointments

The manufacture of ophthalmic ointments is much more complex than the production of ocular liquid therapies and presents several unique challenges. It is essential for drug developers to choose outsourcing partners with extensive manufacturing experience with these specialized capabilities in …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

June 14 – Inhalation Delivery
June 21 – Bioavailability